secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2022-11-16T23:59:59+00:00
Accession:  0001178913-22-004061
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Israeli court approves Chemomab repurchase of 582,023 ADSs from co-founders
---------------------------------------------------------------------------

- Approved repurchase of up to 582,023 ADSs for approx. $1,213,400 to help co-founders pay tax.
- Tax liability stems from merger deferral that expires March 16, 2023.
- Repurchase at market price to avoid bulk sales that could depress CMMB ADS price.
- Company says cash runway unchanged, expected through end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322004061/0001178913-22-004061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322004061/zk2228768.htm
  HTML page:      https://secwatch.observer/filing/0001178913-22-004061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer